Stock Markets June 30, 2026 09:17 AM

EU opens antitrust probe into Align Technology over alleged tying of scanners and aligners

Shares dip after European Commission launches investigation into whether iTero buyers were steered to Invisalign products in the EEA

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
ALGN

Align Technology saw its stock decline after the European Commission announced a formal antitrust inquiry into whether the company tied purchases of its iTero intra-oral scanners to use of its Invisalign clear aligners within the European Economic Area. The probe follows a complaint from a competitor and will assess whether such tying practices violate EU competition rules.

EU opens antitrust probe into Align Technology over alleged tying of scanners and aligners
ALGN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • European Commission has launched a formal antitrust investigation into Align Technology over suspected tying of iTero scanners to Invisalign aligners in the European Economic Area.
  • The investigation was initiated after a competitor lodged a complaint and will assess potential breaches of EU competition rules related to tying.
  • Immediate market impact included a 2% decline in Align Technology's shares on the trading day following the announcement - sectors affected include dental equipment, medical devices, and healthcare services.

Overview

Shares of Align Technology (NASDAQ:ALGN) fell 2% on Tuesday after the European Commission said it has opened an antitrust investigation into the company. The inquiry will examine whether Align engaged in tying - specifically, whether customers who buy the company's iTero intra-oral scanners in the European Economic Area were required or pressured to use Invisalign clear aligners.

What the investigation covers

The European Commission's probe is focused on potential breaches of EU competition rules related to tying practices. According to the announcement, the investigation was launched following a complaint from a competitor. The Commission will evaluate the company's commercial practices around sales of iTero scanners and any conditions attached to those sales that could limit customer choice in orthodontic treatment products.

Company products at the center

Align, a United States-based manufacturer, produces both the iTero intra-oral scanners used by dental and orthodontic practitioners to capture digital impressions of patients' teeth, and Invisalign clear aligners used in orthodontic care. The probe will specifically look at whether Align required or effectively tied scanner purchasers to using its Invisalign aligners.

Market reaction

Stocks moved lower on the news, with Align shares slipping 2% on Tuesday. The price reaction reflects investor sensitivity to regulatory risks that can affect commercial arrangements and competitive dynamics in markets for clinical equipment and treatment products.

Context and limits

The European Commission's announcement notes the investigation was prompted by a competitor complaint. Beyond that procedural information, the Commission will carry out its assessment under relevant EU competition rules. The statement does not provide additional facts about specific contracts, customers, or alleged commercial terms. The scope of the probe is confined to the European Economic Area and to the question of tying in relation to iTero scanners and Invisalign aligners.

Implications to watch

At this stage, the inquiry is investigatory. It will determine whether there is evidence of tying that would constitute a breach of competition law in the EEA. Any further developments, findings, or formal charges would be announced by the European Commission as the process advances.


Summary of facts

  • European Commission opened an antitrust investigation into Align Technology over suspected tying of iTero scanners to Invisalign aligners in the EEA.
  • The probe was triggered by a competitor's complaint.
  • Align is a U.S.-based maker of both iTero scanners and Invisalign clear aligners.
  • Align shares fell 2% on Tuesday following the announcement.

Risks

  • Regulatory risk - the European Commission's probe could lead to findings that alter commercial arrangements between scanner suppliers and aligner providers, affecting revenue streams in the dental equipment and orthodontics sectors.
  • Market reaction risk - investor sentiment can be sensitive to antitrust inquiries, as shown by the 2% share decline, potentially increasing short-term volatility for the company's stock.
  • Geographic scope uncertainty - the investigation covers the European Economic Area, which introduces region-specific legal exposure for the company's operations and sales in that market.

More from Stock Markets

Aduro Clean Technologies Shares Tick Higher After AstroTurf Recycling Memorandum Jun 30, 2026 Circle Internet Shares Plunge After Consortium Launches Competing U.S. Dollar Stablecoin Jun 30, 2026 Tel Aviv Stocks Close Higher as Tech, Biomed and Communications Lead Gains Jun 30, 2026 Oslo stocks slip as media, transport and financials weigh; OBX down marginally Jun 30, 2026 Athens bourse slips as Telecoms, Household and Basic Resources weigh; benchmark down 0.31% Jun 30, 2026